Selvi Ramasamy

Title: Selvi Ramasamy: Innovator in Oligonucleotide Technologies

Introduction

Selvi Ramasamy is a notable inventor based in Wayland, MA (US), recognized for her contributions to the field of oligonucleotide compositions. With a focus on developing technologies for treating muscular dystrophy, her work has significant implications for patients suffering from this debilitating condition.

Latest Patents

Selvi Ramasamy holds a patent for "Oligonucleotide compositions and methods of use thereof." This patent encompasses designed DMD oligonucleotides, compositions, and methods that are instrumental in repairing mutant DMD transcripts. The technologies provided in her patent are particularly useful for skipping exon 51 or exon 53, allowing the transcript to be translated into a truncated but partially functional Dystrophin protein variant. Additionally, her work includes methods for modulating DMD transcript splicing, which can alter the splicing of dystrophin (DMD) transcripts. These advancements are crucial for treating diseases such as Duchenne muscular dystrophy and Becker's muscular dystrophy.

Career Highlights

Selvi Ramasamy is currently associated with Wave Life Sciences Ltd., where she continues to innovate in the field of genetic therapies. Her expertise and dedication to research have positioned her as a key figure in the development of treatments for muscular dystrophy.

Collaborations

Selvi collaborates with talented individuals such as Jason Jingxin Zhang and Chandra Vargeese, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Selvi Ramasamy's work in oligonucleotide technologies represents a significant advancement in the treatment of muscular dystrophy. Her contributions are paving the way for new therapeutic approaches that can improve the quality of life for many patients.